Unlocking the potential of
genomic medicine

News Release

View printer-friendly version << Back
Appointment of Nomura-Code as Joint-Broker

Medgenics (LSE: MEDG, MEDU), the company that is developing a novel approach to the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is proud to announce today the appointment of Nomura Code Securities as joint-broker to the Company with SVS Securities plc with immediate effect.

Commenting on the new appointment Dr. Andrew Pearlman, CEO of Medgenics said: "We are delighted by this new appointment and believe that the combination of Nomura Code Securities, with acknowledged expertise in the life sciences space and its reputation amongst institutional investors, and SVS Securities plc, with its small cap investor expertise, greatly strengthens Medgenics broking team to support the Company going forward"

For further information, please contact:

Andrew Pearlman                                               + 972 4 902 8900

CEO, Medgenics, Inc


Mike Wort / Anna Dunphy                                   + 44 207 861 3838

De Facto Communications


Jonathan Senior                                                 +44 207 776 1219

Nomura Code


Ian Callaway / Alex Mattey                                 +44 207 638 5600

SVS Securities


James Pinner / Derek Crowhurst                         +44 207 444 0800

Religare Capital Markets (Nomad)

This information is provided by RNS
The company news service from the London Stock Exchange